Zynx Health has announced that it has published a new, publicly available review of vaccine administration guidelines specific to COVID-19 vaccines, including Pfizer/BioNTech BNT162b2, the COVID-19 vaccine co-developed by Pfizer and BioNTech, following its emergency use approval by the US Food and Drug Administration (FDA). Concurrently, Zynx has published a comparison table spotlighting the primary characteristics of and differences between five COVID-19 vaccines in late-stage development.
The Zynx Health review of vaccine administration guidelines, drawn primarily from the Centers for Disease Control and Prevention and the most recent meeting of the FDA Advisory Committee on Immunization Practices, features detailed suggestions for hospital and health system operations staff and other healthcare providers as they develop a plan to administer an unprecedented number of vaccinations over 2021.
Zynx Health has also developed a new, easy-to-read COVID-19 vaccine comparison table, which includes information on vaccines from the companies including Pfizer/BioNTech, Moderna, Novavax, AstraZeneca, and Johnson & Johnson.
The table features specifics about each vaccine including FDA approval status, efficacy, side effects, storage, platform, age range, and administration route.
The vaccine administration guidelines and comparison data are available at no cost.
Zynx Health’s complimentary COVID-19 Vaccination Recommendations and COVID-19 Vaccine Comparison Table, as well as additional COVID-19 evidence-based content, are available at zynxhealth.com.
Click here to read the original press release.
